

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Phase 3 trial of monoclonal antibodies, physician-delivered messages for COVID-19 behaviours, vaccination plus non-pharmaceutical interventions

#### Peer reviewed journals featured:

- Randomised clinical trials of:
  - Monoclonal antibodies amlanivimab plus etesevimab, for patients with mild or moderate COVID-19 [here](#)
  - The effect of physician-delivered messages on COVID-19 preventive behaviours [here](#) and associated commentary [here](#)
- A phase 1/2 trial of an inactivated SARS-CoV-2 vaccine (Sinopharm) in healthy adults [here](#)
- Modelling studies on:
  - Integrated vaccination and non-pharmaceutical intervention strategies [here](#)
  - Under-recognised COVID-19 deaths in the US [here](#)
- Observational studies on:
  - Laboratory markers characterising hospitalised and ambulatory COVID-19 patients [here](#)
  - Immune responses to SARS-CoV-2 variants after heterologous and homologous AstraZeneca/Pfizer vaccination [here](#)
  - Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK [here](#)
- Commentary on pandemics and the links between viruses and autoimmunity [here](#)

#### Letters and correspondence discussed:

- Case reports of paraesthesia variant of Guillain-Barré syndrome following AstraZeneca vaccine [here](#)
- Heterologous AstraZeneca and Moderna vaccination [here](#)
- Durable humoral and cellular immune responses 8 months after Johnson & Johnson vaccine [here](#)

#### Guidance and reports

- The World Health Organization published guidance on safe Eid al Adha in the context of COVID-19 [here](#)

## News and blogs

- France and Greece make vaccination mandatory for healthcare workers [here](#)
- ‘Super antibodies’ that maximise breadth and resistance to escape [here](#)
- Regulators warn that rare Guillain-Barré cases may link to Janssen and AstraZeneca vaccines [here](#)
- “Freedom day” in England could lead to “a significant third wave of hospitalisations and deaths” [here](#)
- The pros and cons of “Freedom day” [here](#)
- Why England’s COVID-19 ‘Freedom day’ alarms researchers [here](#)
- Post-acute COVID-19 syndrome and kids [here](#)
- A NEJM audio interview on monoclonal antibodies and vaccine boosters [here](#)
- Lasting immunity after COVID-19, with a big boost from vaccination [here](#)

[Click here](#) to subscribe to the daily evidence digest.

## Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), and [surgery and COVID-19](#).